Hey Cuprum, I had the same question the other day on one of the other threads. I too would like to get some objective opinions on that path also. But, unfortunately there's a lot of cabbage and cows**t to sift through on this forum at times. The best I can come up with so far;
We know back in 2022 Antisense released the results on a Phase IIa clinical trial involving patients with relapsing-remitting MS, where ATL1102 demonstrated a reduction in disease. There was a 54% decrease in the cumulative number of new active brain lesions compared to placebo.
If the company was to change direction today and start focusing on MS, what would the timeline be picking up from the Phase IIa?
Phase IIb - 2 to 3 years
Phase III trials - 3 to 5 years
Safety studie - 1 to 2 years
Regulatory approval - 1 to 2 years
Market prep - 1 to 2 years
Total - 7-8 years (all going well)
or
ATL1103 with Acromegaly?
Thoughts?
Add to My Watchlist
What is My Watchlist?
